Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade

OBJECTIVE. Delayed responses observed with immune checkpoint blockade (ICB) present a challenge for patients with peritoneal malignancies, who risk early symptomatic disease progression requiring treatment discontinuation. While efforts are ongoing to define the biomarkers of response, it is equally...

Descripción completa

Detalles Bibliográficos
Autores principales: Boland, Julia L., Zhou, Qin, Martin, Madhuri, Callahan, Margaret K., Konner, Jason, O’Cearbhaill, Roisin E., Friedman, Claire F., Tew, William, Makker, Vicky, Grisham, Rachel N., Hensley, Martee L., Zecca, Nicholas, Iasonos, Alexia E., Snyder, Alexandra, Hyman, David M., Sabbatini, Paul, Aghajanian, Carol, Cadoo, Karen A., Zamarin, Dmitriy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613945/
https://www.ncbi.nlm.nih.gov/pubmed/30470581
http://dx.doi.org/10.1016/j.ygyno.2018.11.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613945/
https://www.ncbi.nlm.nih.gov/pubmed/30470581
http://dx.doi.org/10.1016/j.ygyno.2018.11.025

Ejemplares similares